Evidence map›Paper›PMID 38216189›Full record

ArticleBMJ open2024

Randomised, siteless study to compare systematic atrial fibrillation screening using enrichment by a risk prediction model with standard care in a Swedish population aged ≥ 65 years: CONSIDERING-AF study design.

Farzaneh Etminani, Emma Sandgren, Johan Holm, Peter Magnusson, Angelo Modica, Karin Moberg, Thomas Davidsson, Linda Stalpe, Sara Kiflemariam, Ninia Younan and 4 more

Registry-linked trialAbstract readClinical Trial Protocol
In one paragraph

Article in BMJ open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05838781 (DeteCtiON and Stroke PreventIon by MoDEl ScRreenING for Atrial Fibrillation), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05838781 nacompletednot on this map

DeteCtiON and Stroke PreventIon by MoDEl ScRreenING for Atrial Fibrillation

TypeinterventionalSponsorBristol-Myers SquibbRan2023 to 2024Enrolled2,112ConditionsAtrial Fibrillation, Atrial FlutterArmsRisk prediction model, 14-days continuous ECG monitoring
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Systematic, randomized atrial fibrillation screening using detailed phenotyping with a risk prediction model combined with patch electrocardiogram in a Swedish population aged 65 years or older: the CONSIDERING-AF trial.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025
    Trial
  2. Trial
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Farzaneh EtminaniCenter for Applied Intelligent Systems Research in Health (CAISR Health), Halmstad University, Halmstad, Sweden farzaneh.etminani@hh.se.ORCID 0000-0003-2006-6229
Emma SandgrenDepartment of Medicine, Hallands sjukhus Varberg, Varberg, Sweden.
Johan HolmPfizer AB, Stockholm, Sweden.
Peter MagnussonBristol Myers Squibb AB, Solna, Sweden.
Angelo ModicaPfizer AB, Stockholm, Sweden.
Karin MobergSHAARPEC by Hallandia V, Stockholm, Sweden.
Thomas DavidssonSHAARPEC by Hallandia V, Stockholm, Sweden.
Linda StalpeBristol Myers Squibb AB, Solna, Sweden.
Sara KiflemariamBristol Myers Squibb AB, Solna, Sweden.
Ninia YounanDepartment of Medicine, Hallands sjukhus Varberg, Varberg, Sweden.
Purvee ParikhMedical Affairs, Philips, Ambulatory Monitoring and Diagnostics, San Diego, California, USA.
Manish WadhwaMedical Affairs, Philips, Ambulatory Monitoring and Diagnostics, San Diego, California, USA.
Anna SundinBristol Myers Squibb AB, Solna, Sweden.
Johan EngdahlDepartment of Clinical Sciences, Karolinska Institutet, Danderyd University Hospital, Stockholm, Sweden.ORCID 0000-0002-1677-7215

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAtrial fibrillation (AF) is the most common arrhythmia and confers an increased risk of mortality, stroke, heart failure and cognitive decline. There is growing interest in AF screening; however, the most suitable population and device for AF detection remains to be elucidated. Here, we present the design of the CONSIDERING-AF (deteCtiON and Stroke preventIon by moDEl scRreenING for Atrial Fibrillation) study. METHODS AND ANALYSIS: CONSIDERING-AF is a randomised, controlled, siteless, non-blinded diagnostic superiority trial with four parallel groups and a primary endpoint of identifying AF during a 6-month study period set in Region Halland, Sweden. In each group, 740 individuals aged≥65 years will be included. The primary objective is to compare the intervention of AF screening enrichment using a risk prediction model (RPM), followed by 14 days of a continuous ECG patch, with no intervention (standard care). Primary outcome is defined as the incident AF recorded in the Region Halland Information Database after 6 months as compared with standard care. Secondary endpoints include the difference in incident AF between groups enriched or not by the RPM, with and without an invitation to 14 days of continuous ECG recording, and the proportions of oral anticoagulation treatment in the four groups. ETHICS AND DISSEMINATION: This study has ethical approval from the Swedish Ethical Review Authority. Results will be published in peer-reviewed international journals. TRIAL REGISTRATION NUMBER: NCT05838781.

Indexed as

Atrial FibrillationHeart FailureStrokeEquivalence Trials as TopicHumansRandomized Controlled Trials as TopicResearch DesignSwedenCARDIOLOGYEchocardiographyElectronic Health Records

Identifiers

PMID38216189
PMCPMC10806481

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.